01 Research question

  • Can a newly emerging nitazene analogue, protodesnitazene, be reliably identified and quantified in postmortem toxicology specimens and seized drug material using high-resolution mass spectrometry and a validated LC-MS/MS method?
  • What is the tissue distribution and metabolic profile of protodesnitazene in a fatal overdose case, and how do femoral blood concentrations compare with those of previously identified desnitazene compounds?

02 Study design

  • This is a single-case forensic toxicology report involving an overdose with protodesnitazene, combining postmortem tissue analysis with analysis of an associated seized powder.
  • The analytical approach included initial identification by LC-QTOF-HRMS with chromatographic separation to distinguish isomers and spectral and retention time matching against reference standards.
  • A quantitation method employing solid-phase extraction with mixed-mode cartridges and LC-MS/MS in MRM mode was developed and partially validated for non-routine analyses, with concentrations determined in a range of postmortem matrices.

03 Key findings

  • Protodesnitazene was identified in postmortem specimens and in an associated seized powder, representing a previously unreported nitazene analogue in toxicology specimens or drug seizures.
  • Femoral blood concentrations of the parent drug ranged from 77 to 222 ng/mL, which were comparable to previously identified desnitazene compounds.
  • The drug metabolized extensively by N-dealkylation, O-dealkylation, and hydroxylation; glucuronides were not present at high levels in blood but were prominent in urine.

04 AI commentary

This case report provides the first documented identification of protodesnitazene in both postmortem toxicology specimens and a seized powder, extending the known list of nitazene analogues encountered in forensic casework. The use of LC-QTOF-HRMS with chromatographic separation and reference standard matching strengthens the structural identification, while the partially validated LC-MS/MS quantitation method offers a practical approach for non-routine analyses. The femoral blood range of 77-222 ng/mL is placed in context with previously identified desnitazenes, but as a single case, it cannot establish a concentration-effect relationship or a lethal threshold.

The metabolic findings, particularly extensive N-dealkylation, O-dealkylation, and hydroxylation with prominent urinary glucuronides but low blood glucuronides, are consistent with phase I and phase II metabolism typical of many opioids. However, the absence of controlled pharmacokinetic data means the relative contribution of parent drug versus metabolites to toxicity remains uncertain. The detection of protodesnitazene in a seized powder confirms its presence in the illicit drug supply, underscoring the public health concern posed by highly potent μ-opioid receptor agonists. The report does not provide prevalence data or information on how widespread this analogue may be.

05 What this study cannot establish

  • This is a single case report, so the findings cannot be generalized to other overdoses, and no control or comparison group was included; the abstract does not report the decedent's full history, co-ingested substances, or the exact cause of death.
  • The quantitation method was only partially validated for non-routine analyses, and the abstract does not report validation parameters such as limits of detection or quantification, precision, accuracy, or matrix effects.
  • The abstract does not report whether the femoral blood concentrations were measured in central or peripheral blood, the postmortem interval, or whether other matrices were quantitatively analyzed, limiting interpretation of the tissue distribution.

06 What to watch next

  • Full validation of the LC-MS/MS quantitation method for protodesnitazene in postmortem matrices should be conducted, including assessment of precision, accuracy, limits of detection and quantification, and matrix effects, to support routine forensic use.
  • Additional case reports and systematic surveillance of nitazene analogues in toxicology specimens and seized powders are needed to establish typical concentration ranges, metabolite patterns, and potential toxicity thresholds for protodesnitazene and related compounds.

Original abstract and source

Multiple new analogues from the 2-benzyl benzimidazole or "nitazene" class of drugs have emerged on the drug market in recent years. Nitazenes are highly potent μ-opioid receptor agonists that present a substantial public health concern due to their elevated risk of severe toxicity in overdose and their significant potential for misuse. We report on a case involving an overdose with another new analogue from this class, protodesnitazene. The drug has a similar potency to fentanyl and has not been previously reported in toxicology specimens or drug seizures. Protodesnitazene was initially identified by LC-QTOF-HRMS (High Resolution Mass Spectrometry) and distinguished from relevant isomers by chromatographic separation, with spectral and retention time matching against reference standards. A quantitation method employing solid phase extraction using mixed mode cartridges and utilizing LC-MS/MS operating in MRM mode was developed and partially validated for non-routine analyses. Concentrations for the parent drug were determined in a range of postmortem matrices and femoral blood levels (77-222 ng/mL) were found to be comparable to previously identified desnitazene compounds. Protodesnitazene was observed to metabolize extensively by N-dealkylation, O-dealkylation, and hydroxylation. Glucuronides were not present at high levels in the blood but were prominent in the urine. Protodesnitazene was also identified in an associated seized powder.

Open the original paper ↗